



PTO/SB/08B(04-07)

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 6

Complete if Known

Application Number	10/580,999
Filing Date	March 12, 2007
First Named Inventor	Julia Y. LJUBIMOVA
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	67789-586

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	ALBINI et al., A Rapid In Vitro Assay For Quantitating The Invasive Potential Of Tumor Cells, Cancer Research, (June 15, 1987), pp. 3239-3245, 47(12).	
	2	ANDREWS et al., Results Of A Pilot Study Involving The Use Of An Antisense Oligodeoxynucleotide Directed Against The Insulin-Like Growth Factor Type I Receptor In Malignant Astrocytomas, Journal of Clinical Oncology, (April 15, 2001), pp. 2189-2200, 19(8).	
	3	ARORA et al., c- Myc Antisense Limits Rat Liver Regeneration And Indicates Role For c-myc In Regulating Cytochrome P-450 3A Activity, Journal of Pharmacology And Experimental Therapeutics, (March 2000), pp. 921-928, 292(3).	
	4	ASTRIAB-FISHER et al., Antisense Inhibition Of P- Glycoprotein Expression Using Peptide-Oligonucleotide Conjugates, Biochemical Pharmacology (July 1, 2000), pp. 83- 90, 60(1).	
	5	BELKIN et al., Integrins As Receptors For Laminins, Microscopy Research and Technique, (November 1, 2000), pp. 280-301, 51(3).	
	6	BELLO et al., Simultaneous Inhibition Of Glioma Angiogenesis, Cell Proliferation, And Invasion By A Naturally Occurring Fragment Of Human Metalloproteinase-2, Cancer Research, (December 15, 2001), pp. 8730-8736, 61(24).	
	7	BOADO et al., Antisense-Mediated Down-Regulation Of The Human Huntingtin Gene, Journal of Pharmacology and Experimental Therapy, (October 2000), pp. 239-243, 295(1).	
	8	COLOGNATO et al., Form And Function: The Laminin Family Of Heterotrimers, Developmental Dynamics, (June 2000), pp. 213-234, 218(2).	
	9	De DIESBACH et al., Identification, Purification and Partial Characterisation Of An Oligonucleotide Receptor In Membranes Of HepG2 Cells, Nucleic Acids Research, (February 15, 2000), pp. 868-874, 28(4).	
	10	DIAS et al., Antisense Oligonucleotides : Basic Concepts And Mechanisms, Molecular Cancer Therapy, (March 2002), pp. 347-355, 1(5).	
	11	FUJIWARA et al., Purification And Characterization Of Human Laminin-8. Laminin-8 Stimulates Cell Adhesion And Migration Through $\alpha 3 \beta 1$ and $\alpha 6 \beta 1$ Integrins, Journal of Biological Chemistry, (May 18, 2001), pp. 17550-17558, 276(20).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

PTO/SB/08B(04-07)

Approved for use through 09/30/2007. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/580,999	
			Filing Date	March 12, 2007	
			First Named Inventor	Julia Y. LJUBIMOVA	
			Art Unit	To be assigned	
			Examiner Name	To be assigned	
Sheet	2	of	6	Attorney Docket Number	67789-586

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	12	GONZALEZ et al., Complex Interactions Between The Laminin a4 Subunit And Integrins Regulate Endothelial Cell Behavior In Vitro And Angiogenesis In Vivo, Proceedings of the National Academy of Sciences USA, (December 10, 2002), pp. 16075-16080, 99(25).	
	13	HAYASHI et al., Identification And Recombinant Production Of Human Laminin a4 Subunit Splice Variants, Biochemical and Biophysical Research Communications, (December 6, 2002), pp. 498-504, 299(3).	
	14	HEROLD-MENDE et al., Clinical Impact And Functional Aspects Of Tenascin-C Expression During Glioma Progression, International Journal Of Cancer, (March 20, 2002), pp. 362-369, 98(3).	
	15	JANSEN et al., Chemosensitisation Of Malignant Melanoma By BCL2 Antisense Therapy, Lancet, (November 18, 2000), pp. 1728-1733, 356(9243).	
	16	KACHRA et al., Expression Of Matrix Metalloproteinases And Their Inhibitors In Human Brain Tumors, Clinical and Experimental Metastasis, (1999), pp. 555-566, 17(7).	
	17	KLEINMAN et al., Basement Membrane Complexes With Biological Activity, Biochemistry, (January 28, 1986), pp. 312-318, 25(2).	
	18	KNOTT et al., Stimulation Of Extracellular Matrix Components In The Normal Brain By Invading Glioma Cells, International Journal Of Cancer, (March 16, 1998), pp. 864-872, 75(6).	
	19	KOMATA et al., Combination Therapy Of Malignant Glioma Cells With 2-5A-Antisense Telomerase RNA and Recombinant Adenovirus p53, Gene Therapy, (December 2000), pp. 2071-2079, 7(24).	
	20	KONDRAGANTI et al., Selective Suppression Of Matrix Metalloproteinase-9 In Human Glioblastoma Cells By Antisense Gene Transfer Impairs Glioblastoma Cell Invasion, Cancer Research, (December 15, 2000), pp. 6851-6855, 60(24).	
	21	KULLA et al., Tenascin Expression Patterns And Cells Of Monocyte Lineage: Relationship In Human Gliomas, Modern Pathology, (January 2000), pp. 56-67, 13(1).	
	22	LACERRA et al., Restoration Of Hemoglobin A Synthesis In Erythroid Cells From Peripheral Blood Of Thalassemic Patients, Proceedings of the National Academy Of Sciences USA, (August 15, 2000), pp. 9591-9596, 97(17).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

PTO/SB/08B(04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

Application Number	10/580,999
Filing Date	March 12, 2007
First Named Inventor	Julia Y. LJUBIMOVA
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	67789-586

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	23	LAL et al., A Public Database For Gene Expression In Human Cancers. Cancer Research, (November 1, 1999), pp. 5403-5407, 59(21).	
	24	LJUBIMOV et al., Human Corneal Basement Membrane Heterogeneity: Topographical Differences In The Expression Of Type IV Collagen And Laminin Isoforms, Lab Investigation, (April 1995), pp. 461-473, 72(4).	
	25	LJUBIMOVA et al., Gene Array Analysis Of Differentially Expressed Genes In Human Glial Tumors. International Journal of Oncology, (2001), pp. 287-295, 18.	
	26	LJUBIMOVA et al., Overexpression Of a4 Chain-Containing Laminins In Human Glial Tumors Identified By Gene Microarray Analysis, Cancer Research (July 15, 2001), pp. 5601-5610, 61(14).	
	27	MacDONALD et al., Urokinase Induces Receptor Mediated Brain Tumor Cell Migration And Invasion, Journal Of Neuro-Oncology, (December 1998), pp. 215-226, 40(3).	
	28	McKEAN et al., FAK Induces Expression Of Prx1 To Promote Tenascin-C-Dependent Fibroblast Migration, Journal of Cell Biology, (April 28, 2003), pp. 393-402, 161(2).	
	29	MINAKAWA et al., In Vitro Interaction Of Astrocytes And Pericytes With Capillary-Like Structures Of Brain Microvessel Endothelium, Lab Investigation, (July 1991), pp. 32-40, 65(1).	
	30	MINER et al., The Laminin Alpha Chains: Expression, Developmental Transitions, and Chromosomal Locations Of A1-5, Identification Of Heterotrimeric Laminins 8-11, and Cloning Of A Novel a3 Isoform, Journal of Cell Biology, (May 5, 1997), pp. 685-701, 137(3).	
	31	NIELSEN et al., Peptide Nucleic Acid Targeting Of Double-Stranded DNA. Methods In Enzymology, 2001, pp. 329-340, 340.	
	32	PATARROYO et al., Laminin Isoforms In Tumor Invasion, Angiogenesis And Metastasis, Seminars . Seminars In Cancer Biology, (June 2002), pp. 197-207, 12(3).	
	33	PETAJANIEMI et al., Localization Of Laminin a4-Chain In Developing And Adult Human Tissues, The Journal Of Histochemistry and Cytochemistry, (August 2002), pp. 1113-1130, 50(8).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

PTO/SB/08B(04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 6

Complete if Known

Application Number	10/580,999
Filing Date	March 12, 2007
First Named Inventor	Julia Y. LJUBIMOVA
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	67789-586

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	34	QIN et al., The Transcription Factors Sp1, Sp3, and AP-2 Are Required For Constitutive Matrix Metalloproteinase-2 Gene Expression In Astrogloma Cells, Journal Of Biological Chemistry, (October 8, 1999), pp. 29130-29137, 274(41).	
	35	SEHGAL, A., Molecular Changes During The Genesis Of Human Gliomas, Seminars In Surgical Oncology, (January-February 1998), pp. 3-12, 14(1).	
	36	SHI et al., Antisense Imaging Of Gene Expression In The Brain In Vivo, Proceeding of National Academy of Sciences USA, (December 19, 2000), pp. 14709-14714, 97(26).	
	37	SIXT et al., Endothelial Cell Laminin Isoforms, Laminins 8 And 10, Play Decisive Roles In T Cell Recruitment Across The Blood-Brain Barrier In Experimental Autoimmune Encephalomyelitis, Journal of Cell Biology, (May 28, 2001), pp. 933-946, 153(5).	
	38	SUMMERTON et al., Morpholino Antisense Oligomers: Design, Preparation And Properties, Antisense And Nucleic Acid Drug Development, (June 1997) pp. 187-195, 7(3).	
	39	TAYLOR et al., Comparison Of Efficacy Of Antisense Oligomers Directed Toward TNF-a In Helper T And Macrophage Cell Lines, Cytokine, (September 1997), pp. 672-681, 9(9).	
	40	THYBOLL et al., Deletion Of The Laminin a4 Chain Leads To Impaired Microvessel Maturation, Molecular and Cellular Biology, (February 2002), pp. 1194-1202, 22(4).	
	41	TSUJI et al., Regulation Of Melanoma Cell Migration And Invasion By Laminin-5 And a3B1 Integrin (VLA-3), Clinical and Experimental Metastasis, (2002), pp. 127-134, 19(2).	
	42	VOYTA et al., Identification And Isolation Of Endothelial Cells Based On Their Increased Uptake Of Acetylated-Low Density Lipoprotein, Journal Of Cell Biology, (December 1984), pp. 2034-2040, 99(6).	
	43	ZAGZAG et al., Angiogenesis In The Central Nervous System: A Role For Vascular Endothelial Growth Factor/Vascular Permeability Factor And Tenascin-C. Common Molecular Effectors In Cerebral Neoplastic And Non-Neoplastic "Angiogenic Diseases", Histo Histopathol, 17: 301-321, 2002.	
	44	AGRAWAL et al., Antisense Therapeutics: Is It As Simple As Complementary Base Recognition?, Molecular Medicine Today, (February 2000), pp. 72-81, 6.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

PTO/SB/08B(04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 6

Complete if Known

Application Number	10/580,999
Filing Date	March 12, 2007
First Named Inventor	Julia Y. LJUBIMOVA
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	67789-586

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	45	GEWIRTZ et al., Facilitating Oligonucleotide Delivery: Helping Antisense Deliver On Its Promise, Proceedings of the National Academy of Sciences of USA, (April 1996), pp. 3161-3163, 93.	
	46	FUJITA et al., Inhibition of Laminin-8 In Vivo Using A Novel Poly(Malic Acid)-Based Carrier Reduces Glioma Angiogenesis, Angiogenesis, (2006), pp. 183-191, 9.	
	47	KHAZENZON et al., Antisense Inhibition of Laminin-8 Expression Reduces Invasion of Human Gliomas In Vitro, Molecular Cancer Therapeutics, (2003), pp. 985-994, 2.	
	48	LU et al., Delivering siRNA In Vivo For Functional Genomics and Novel Therapeutics, RNA Interference Technology, (2005), pp. 303-317.	
	49	NIELSEN, P.E., The Last Hurdle?, Gene Therapy, (2005), pp. 956-957, 12.	
	50	SAMARSKY et al., RNAi In Drug Development: Practical Considerations, RNA Interference Technology, (2005), pp. 384-395.	
	51	BICKEL et al., Delivery of Peptides and Proteins Through The Blood-Brain Barrier, Advanced Drug Delivery Reviews, (2001), pp. 247-279, 46.	
	52	BOADO et al., Drug Delivery of Antisense Molecules To The Brain For Treatment of Alzheimer's Disease and Cerebral AIDS, Journal of Pharmacological Science, (1998), pp. 1308-1315, 87.	
	53	BROADWELL et al., Transcytosis of Protein Through The Mammalian Cerebral Epithelium and Endothelium III Receptor-Mediated Transcytosis Through The Blood-Brain-Barrier of Blood-Borne Transferrin and Antibody Against The Transferrin Receptor, Experimental Neurology, (1996), pp. 47-65, 142.	
	54	BULMUS et al., A New pH-Responsive and Glutathione-Reactive, Endosomal Membrane-Disruptive Polymeric Carrier For Intracellular Delivery of Biomolecular Drugs, Journal of Controlled Release, (2003), pp. 105-120, 93.	
	55	CAMMAS et al., Polymers of Malic Acid and 3-Alkylmalic Acid As Synthetic PHAs In The Design of Biocompatible Hydrolyzable Devices, International Journal of Biological Macromolecules, (1999), pp. 273-282, 25.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

PTO/SB/08B(04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 6 of 6

Complete if Known

Application Number	10/580,999
Filing Date	March 12, 2007
First Named Inventor	Julia Y. LJUBIMOVA
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	67789-586

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite. No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	56	FISCHER et al., An Unusual Polyanion From Physarum Polycephalum That Inhibits Homologous DNA Polymerase A In Vitro, Biochemistry, (1989), pp. 5219-5226, 28.	
	57	IWATA et al., A Novel Surgical Glue Composed of Gelatin and N-Hydroxysuccinimide Activate Poly(L-Glutamic Acid): Part 1 Synthesis of Activated Poly(L-Glutamic Acid) and Its Gelation With Gelatin, Biomaterials, (1998), pp. 1869-1876, 19.	
	58	KOPECEK et al., HPMA Copolymer-Anticancer Drug Conjugates: Design, Activity, and Mechanism of Action, European Journal of Biopharmacology, (2000), pp. 61-81, 50.	
	59	KORHERR et al., Poly (β-1-Malate) Hydrolase From Plasmodia of Physarum Polycephalum, Canadian Journal of Microbiology, (1995), pp. 192-199, 41(Suppl. 1).	
	60	KURIHARA et al., Epidermal Growth Factor Radiopharmaceuticals: 111m Cheladon, Conjugation To A Blood-Brain Barrier Delivery Vector Via A Biotin-Polyethylene Linker, Pharmacokinetics, and In Vivo Imaging of Experimental Brain Tumors, Bioconjugate Chemistry, (1999), pp. 505-511, 10.	
	61	LEE et al., Effects of Culture Conditions on β-Poly (l-Malate) Production by Physarum Polycephalum, Applied Microbiology and Biotechnology, (1999), pp. 647-652, 51.	
	62	PICHON et al., Histidine-Rich Peptides and Polymers For Nucleic Acid Delivery, Advanced Drug Delivery Reviews, (2001), pp. 75-94, 53.	
	63	SAITO et al., Drug Delivery Strategy Utilizing Conjugation Via Reversible Disulfide Linkages: Role and Site of Cellular Reducing Activities, Advanced Drug Delivery Reviews, (2003), pp. 199-215, 55.	
	64	SCHNAIBLE et al., Identification of Fluorescein-5'-Isothiocyanate-Modification Sites In Proteins By Electrospray-Ionization Mass Spectroscopy, Bioconjugate Chemistry, (1999), pp. 861-866, 10.	
	65	SHI et al., Noninvasive Gene Targeting To The Brain, Proceedings of the National Academy of Sciences, (2000), pp. 7567-7572, 97.	
	66	WILLNER et al., (6-Maleimidocaproyl) Hydrazone of Doxorubicin - A New Derivative For The Preparation of Immunoconjugates of Doxorubicin, Bioconjugate Chemistry, (1993), pp. 521-527, 1993.	

Examiner Signature	/Jennifer Pitrak/	Date Considered	01/13/2009
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./